Thomas Sisson is a Respiratory physician. OpenAlex indexes 92 publications with 5,312 citations (h-index 37).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 East Medical Center Dr
3rd Floor Taubman Ctr Recp C
Ann Arbor, MI 481095360
Telephone
734-647-9342Registry record last updated 13 Apr 2012.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Mylan Specialty L.P.Program year20241 payment
- Chiesi USA, Inc.Program year20221 payment
- Chiesi USA, Inc.Program year20216 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
41.1%Other respiratory system products19.5%Trikafta100%Part D≥13 patientsbeta2-Adrenergic Agonist9.6%Albuterol Sulfate Hfa100%Part D≥23 patients+ 2 more classes in this area
Metabolism & gastrointestinal
31.7%Corticosteroid15%Prednisone100%Part D≥21 patientsAntidiarrheal microorganisms10.2%Creon100%Part D<11 patients+ 1 more class in this area
Anti-infectives
20.6%Macrolide Antimicrobial8.4%Azithromycin100%Part D<11 patientsAminoglycoside Antibacterial5.1%Amikacin Sulfate100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2000–2026 per NIH RePORTER. The latest:
- A Novel PAI-1 Function Drives Lung Fibrosis
University of Michigan at Ann Arbor
FY2026$692,404R01HL163870 - A Novel PAI-1 Function Drives Lung Fibrosis
University of Michigan at Ann Arbor
FY2025$706,535R01HL163870 - A Novel PAI-1 Function Drives Lung Fibrosis
University of Michigan at Ann Arbor
FY2024$695,226R01HL163870
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Diverse Injury Pathways Induce Alveolar Epithelial Cell CCL2/12, Which Promotes Lung Fibrosis
American Journal of Respiratory Cell and Molecular Biology
2020 - Urokinase Plasminogen Activator Overexpression Reverses Established Lung Fibrosis
Thrombosis and Haemostasis
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”